Physician profile
Daniel G Tinker
NPI 1417449869
$111,590.53
in general payments reported to CMS, 2019-2025
31 companies · $91K in 2025
The $91K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $121 · 2021: $1,094 · 2022: $4,927 · 2023: $4,230 · 2024: $10K · 2025: $91K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Food and Beverage: $20K · Consulting Fee: $4,353 · Travel and Lodging: $3,772 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,333.00 |
| Food and Beverage | $20,289.55 |
| Consulting Fee | $4,352.50 |
| Travel and Lodging | $3,771.72 |
| Education | $104.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $81,110.47 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $7,913.27 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,056.10 | 2022-2025 | Sotyktu |
| Allergan, INC. | $2,762.52 | 2022 | |
| Arcutis Biotherapeutics, INC. | $2,336.40 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $2,139.69 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Abbvie INC. | $1,873.18 | 2021-2025 | Skyrizi |
| Pfizer INC. | $1,400.37 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,169.46 | 2019-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $1,039.52 | 2023-2024 | Vtama |
| Leo Pharma INC. | $854.64 | 2024-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $829.19 | 2024-2025 | |
| Journey Medical Corporation | $776.80 | 2020-2025 | |
| Amgen INC. | $601.18 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $591.21 | 2021-2025 | Opzelura |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $489.90 | 2024-2025 | Ebglyss, Taltz, Zepbound |
| Janssen Biotech, INC. | $453.69 | 2024-2025 | Tremfya |
| Botanix Sb INC | $320.17 | 2025 | Sofdra |
| Sun Pharmaceutical Industries INC. | $302.45 | 2025 | |
| Almirall LLC | $285.48 | 2022-2025 | Klisyri, Seysara |
| Biofrontera INC. | $213.21 | 2024-2025 | Ameluz, Rhodoled Xl, Xepi |
| Epi Health, LLC | $157.86 | 2022 | |
| Organogenesis INC. | $124.68 | 2025 | Puraply Wound Matrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.48 | 2024 | Spevigo |
| Organon LLC | $93.23 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $76.56 | 2024-2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $40.21 | 2025 | Clear+Brilliant |
| Revance Therapeutics, INC. | $23.99 | 2024 | Daxxify |
| Stemline Therapeutics INC. | $22.32 | 2022 | |
| Exeltis, USA INC. | $18.21 | 2024 | Slynd |
| Strata Skin Sciences, INC. | $14.09 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tinker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.